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PENGENALAN METABOLIT BERAT MOLEKUL RENDAH  YANG 
BOLEH MERAMAL TOKSISITI GASTRIK DAN KERINTANGAN 
TERARUH ASPIRIN DOS RENDAH DALAM TIKUS DAN DALAM 
KALANGAN PESAKIT KORONARI ARTERI YANG STABIL 
MENGGUNAKAN FARMAKOMETABONOMIK BERASASKAN NMR 
ABSTRAK 
Aspirin Dos Rendah (LDA) merupakan asas dalam pencegahan sekunder bagi 
penyakit koronari arteri (CAD). Walaupun terbukti keberkesanannya, ketoksikan 
gastro-usus menjadi kekurangan utama. Sebagai tambahan, sesetengah pesakit masih 
mengalami peristiwa atherotrombotik semasa mengambil profilaksis sekunder aspirin, 
istilah ini dikenali sebagai kerintangan aspirin. Punca sesetengah orang mengalami 
ketoksikan gastrik yang serius manakala yang lain tidak masih belum difahami dengan 
jelas. Begitu juga tiada penjelasan yang tepat bagi punca mengapa sesetengah pesakit 
terhindar daripada mengalami peristiwa sekunder manakala yang lain masih 
mengalaminya sekali lagi. Tujuan kajian ini adalah untuk menilai penggunaan 
farmakometabonomik dalam mencari metabolit baru yang boleh meramalkan 
ketoksikan gastrik aruhan aspirin dan kerintangan aspirin dalam tikus. Kajian ini juga 
bertujuan untuk mengesahkan metabolit tersebut dalam pesakit penyakit arteri 
koronari. Kajian ini melibatkan 2 fasa, iaitu fasa penemuan dalam tikus dan fasa 
pengesahan dalam manusia. Model pra-dos telah dibangunkan menggunakan data 
spektroskopi H-NMR dari cecair bio tikus Sprague Dawley (SD) dan identiti kelas 
masing-masing dalam tikus. Data pada awalnya menjalani analisis statistik multivariat 
termasuk analisis komponen utama dan analisis orthogonal-partial least square 
discriminant. Data kemudian dikelaskan kepada kumpulan yang mengalami kesan 
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toksik gastrik berbanding  kumpulan yang tidak mengalami kesan toksik gastrik atau  
kumpulan yang mengalami kerintangan aspirin berbanding kumpulan yang sensitif 
aspirin untuk kajian ketoksikan gastrik dan seterusnya kajian kerintangan aspirin. 
Analisis statistik multivariat, daripada model-model yang telah dibangunkan, 
menunjukkan pemisahan yang signifikan antara 2 kelas dalam setiap kes. Hal ini  juga 
membawa kepada pengenalpastian metabolit yang telah diskriminasi yang disahkan 
menggunakan pangkalan data metabolit. Analisa urin farmakometabonomik pra-dos 
telah mengenalpasti sitrat, metilamina, trimetilamina  N-oksida dan hipurat sebagai 
biopenanda untuk toksisiti gastrik yang disebabkan oleh aspirin. Juga, analisis serum 
farmakometabonomik pra-dos mengenal pasti valina, laktat, asetoasetat dan piruvat 
sebagai biopenanda untuk toksisiti gastrik yang disebabkan oleh aspirin. Lactat, 
trimetilamina N-oksida dan 4-hidroksifenilasetat telah dikenalpasti sebagai penanda 
bio untuk kerintangan aspirin. Seterusnya, model yang dibangunkan dengan 
menggunakan data daripada tikus divalidasi dengan menggunakan model yang 
diperolehi daripada data pesakit manusia. Secara keseluruhan, daripada 6 model yang 
divalidasi (4 untuk ketoksikan gastrik dan 2 untuk rintangan aspirin), 5 model 
mempunyai kejituan yang sangat baik (nilai, >97%), semua model mempunyai 
ketepatan yang baik (nilai, >50%) dan 4 model mempunyai kesensitifan yang rendah 
(nilai, <5%). Kesensitifan yang rendah menunjukkan bahawa model yang 
dibangunkan menggunakan tikus tidak dapat diterjemahkan dengan sempurna untuk 
meramalkan ketoksikan gastrik dan / atau rintangan aspirin LDA dalam manusia. Oleh 
itu, kajian masa depan bagi membangunkan dan mengesahkan model perlu 
menggunakan spesies yang sama untuk mengelakkan masalah ini. 
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IDENTIFICATION OF LOW MOLECULAR WEIGHT 
METABOLITES THAT CAN PREDICT LOW DOSE ASPIRIN INDUCED 
GASTRIC TOXICITY AND RESISTANCE IN RATS AND STABLE 




Low Dose Aspirin (LDA) is the cornerstone of secondary prevention in 
coronary artery disease (CAD). Despite its established efficacy, it suffers a major 
setback of causing gastrointestinal toxicity. In addition, some patients still experience 
atherothrombotic events while on aspirin secondary prophylaxis, a term known as 
aspirin resistance. The reasons why some people experience its serious gastric toxicity 
while others do not is still poorly understood. Likewise, the reason why some patients 
are adequately protected from a secondary event while others experience another event 
is yet to be adequately understood. The aim of this project was to evaluate the use of 
pharmacometabonomics, in finding novel metabolites that can predict aspirin-induced 
gastric toxicity and aspirin resistance in rats. It also aimed at validating such 
metabolites in CAD patients. The study involved 2 phases, namely the discovery phase 
in rats and the validation phase in humans. Pre-dose models were developed using H-
NMR spectroscopic data from the biofluids of Sprague Dawley (SD) rats and the 
respective class identities of the rats. The data were initially subjected to multivariate 
statistical analysis including principal component analysis and orthogonal-partial least 
square discriminant analysis. The class identities were either gastric toxic versus non-
gastric toxic or aspirin resistant versus aspirin sensitive for the gastric toxicity and 
aspirin resistance studies respectively. The multivariate statistical analysis, from which 
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the models were developed, showed a significant separation between the 2 classes in 
each case. They also led to identification of discriminating metabolites which were 
confirmed using metabolite databases. Pre-dose pharmacometabonomic urine analysis 
identified citrate, methylamine, trimethylamine N-oxide and hippurate as biomarkers 
for aspirin-induced gastric toxicity. Also, pre-dose pharmacometabonomic serum 
analysis identified valine, lactate, acetoacetate and pyruvate as biomarkers for aspirin-
induced gastric toxicity. Lactate, trimethylamine N-oxide and 4-hydroxyphenylacetate 
were identified as biomarkers for aspirin resistance. Finally, the models developed 
using the data from rats were validated with models developed using data from human 
patients. Overall, out of the 6 validated models (4 for gastric toxicity and 2 for aspirin 
resistance), 5 models had an excellent specificity (value, >97%), all models had a good 
accuracy (value, >50%) and 4 models had a poor sensitivity (value, <5%). The poor 
sensitivity indicates that models developed using rats could not perfectly translate to 
predict LDA-induced gastric toxicity and/or aspirin resistance in humans as they did 
in the rats. Future studies should therefore develop and validate a model using the same 
species to avoid this problem.
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CHAPTER 1  
 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Research background 
1.1.1 The burden of cardiovascular diseases (CVDs) 
Cardiovascular diseases (CVD) are diseases that affect the heart, such as coronary heart 
disease, stroke, heart failure and hypertension (Benjamin et al., 2018). According to the 
Heart disease and statistics, 2018, CVDs are the principal cause of mortality worldwide 
(Benjamin et al., 2018). Just like other countries, the burden of CVD also greatly affects 
Malaysia. It remains the principal cause of death for more than a decade in Malaysia, 
accounting for 20-25% of all deaths in public hospitals (Ministry of Health, 2014). Among 
the CVDs, Coronary Artery Disease (CAD) is the leading cause of such mortalities. In 
2017, CAD accounted for 13.9% of all recorded deaths (168,168 deaths) in Malaysia 
(Department of Statistics Malaysia, 2018). 
1.1.2 Coronary artery disease 
Coronary Artery Disease is a condition in which the vascular supply to the heart is 
obstructed by fat, occlusion or spasm of coronary arteries (Mcrobbie, 2011). This may 
impair the provision of aerated blood to cardiac tissue sufficiently to cause cardiac muscle 
ischemia that, if severe or prolonged, could cause the death of heart muscle cells 
(Mcrobbie, 2011). The terms, “Coronary Artery Disease, Coronary Heart Disease (CHD) 
and ischaemic heart disease (IHD)”, are often used interchangeably (Mcrobbie, 2011). 
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However, more specifically, CAD refers to atherosclerotic involvement of the coronary 
arteries, while IHD is usually used to refer to the presentation of clinical symptoms and 
CHD often includes other factors leading to insufficient blood flow to heart muscles, such 
as valvular heart disease. The term CAD will be used subsequently throughout this thesis 
and is used to refer to atherosclerotic heart disease affecting the coronary arteries of the 
heart. 
1.1.3 Pathophysiology of coronary artery disease 
Obstruction of blood flow by atheromatous plaques within the coronary arteries is the 
most typical reason behind stable coronary artery disease and low-risk unstable angina. 
Anginal symptoms are a clinical manifestation of ischemia. Risk factors to the 
advancement of CAD include diabetes, hyperlipidaemia, hypertension, obesity, and 
smoking (Abrams, 2005).  
Exposure of the blood vessel epithelial tissue to the products of glycosylation associated 
with diabetes, Low Density Lipoproteins (LDLs), vasoconstrictor hormones associated 
with hypertension, excess adipose tissue or proinflammatory molecules from smoking 
results in the expression of adhesion molecules that permit leukocytes to stay to the blood 
vessel wall. Upon entry into the artery wall, blood monocytes begin to scavenge lipids and 
become foam cells. Macrophage foam cells unleash further cytokines and effector 
molecules that stimulate smooth muscle cell migration from the arterial intima into the 
media, as well as smooth muscle cell proliferation. During this process, the prime fatty 
accumulation of lipoprotein within the blood vessel tissue layer develops into 
atherosclerotic plaques. Ischemic symptoms may manifest resulting from impediment of 
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blood flow due to atherosclerotic plaques or when a clot or vasospasm is overlaid on less 
critical plaques (Libby & Theroux, 2005).  
The focal point for management of CAD should therefore be modifiable risk factor 
reduction through healthy lifestyle, by underscoring weight monitoring and control, 
increasing physical activity, blood pressure control, lipid control, and smoking cessation 
(Fihn et al., 2014). Antiplatelet therapy is recommended for every patient while dual 
antiplatelet therapy may be considered in designated patients (Fihn et al., 2014). Patients 
with chronic symptoms of angina should be furnished systematically with an add-on of 
beta-blockers, calcium-channel antagonists, and/or long-acting nitrates (Fihn et al., 2014). 
Revascularization to diminish symptoms may be necessary in patients with sustained 
angina undeterred by lifestyle adjustments and guideline-directed medical care. Besides, 
simultaneous revascularization, lifestyle adjustments and medical therapy is advocated for 
patients with high possibility of ischemia (Boden et al., 2007). 
1.1.4 Role of platelets in coronary artery disease 
Platelets are non-nucleated, disc-shaped blood components with a lifespan of 7-10 days 
in blood circulation before being removed by the spleen (Patrono & Rocca, 2012). The 
concentration of platelets ranges from 150 - 400 x 109/l of blood. Though, their principal 
function is haemostasis, they provide additional functions such in angiogenesis and innate 
immunity (Dimitrios, Dimitrios, & Konstantinos, 2012; Patrono & Rocca, 2012).  
Platelets are activated in cases of vessel wall injury to form a fine unitary layer over the 
injured endothelium to avert excessive haemorrhage and to additionally initiate the 
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procedures of vessel wall repair. Nonetheless, under certain diseased conditions, they form 
pathogenic, unrestrained aggregates that lead to thrombotic events (Ruggeri, 2002). In 
such scenarios, dysfunction of the endothelium or the presence of atherosclerotic lesions 
leads to platelet adhesion, activation and aggregation. Myocardial ischemia or infarction 
presenting as acute coronary syndromes (ACS) may arise due to thrombotic incidents in 
the coronary arteries subsequent to sudden breakage of an atherosclerotic plaque coupled 
with platelet-mediated coronary vessel constriction and micro-embolization (Dimitrios et 
al., 2012). Inhibition of platelet function is therefore essential in the management of CAD. 
Several mechanisms of inhibition have been postulated, but the Cyclooxygenase (COX) 
inhibition is the most established pathway. 
1.1.5 The cyclooxygenase-1 pathway  
Arachidonic acid is a polyunsaturated fatty acid. It occurs in the phospholipids of 
membranes of the body's cells, and is ample in the brain, muscles, and liver. Arachidonic 
acid is also available in the phospholipids of platelet membrane and it is the major 
precursor of eicosanoids. Eicosanoids are a group of molecules comprising leukotrienes 
and prostanoids (prostacyclins, prostaglandins, and thromboxanes). They are signalling 
molecules made by the enzymatic or non-enzymatic oxidation of arachidonic acid (Smith, 
1987). 
Prostanoids are a sub-type of eicosanoids comprising of the prostaglandins (mediators of 
anaphylactic and inflammatory reactions), thromboxanes (mediators of blood vessel 
constriction), and prostacyclins (functional in the resolution stage of inflammation). 
Prostaglandins (PG) and thromboxane A2 (TXA2), are produced after arachidonic acid 
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(AA) is released from the plasma membrane by phospholipases (PLAs) and metabolized 
by the successive actions of prostaglandin G/H synthase (also known as 
Cyclooxygenases), and other synthases (Ricciotti & FitzGerald, 2011).  
Arachidonic acid is released from the membrane phospholipids by numerous forms of 
PLA, which are activated by various stimuli. Arachidonic acid is converted to the unstable 
intermediate prostaglandin H2 by cytosolic prostaglandin H synthases, which have both 
COX and hydroperoxidase (HOX) activity (Ricciotti & FitzGerald, 2011). Prostaglandin 
production depends on the activity of COX, which occurs as peculiar isoforms referred to 
as COX-1 and COX-2.  
COX-1, which is constitutively found in most cells, is the major source of prostanoids that 
aids homeostasis functions, such as gastric epithelial cyto-protection (Ricciotti & 
FitzGerald, 2011). Meanwhile, COX-2, which is promoted by inflammatory stimuli, 
hormones and growth factors, is the principal source of prostanoids synthesis during 
inflammation and in proliferative diseases, like cancer. Nevertheless, the two enzymes 
contribute to both homeostatic and inflammatory conditions (Ricciotti & FitzGerald, 
2011). 
1.1.6 Thromboxane A2 and B2 
TXA2 plays a distinctively vital role in platelet aggregation. TXA2 is produced by 
activated platelets and acts as a potent vasoconstrictor and stimulator of platelet 
aggregation mainly by increasing platelet expression of glycoprotein IIb/IIIa fibrinogen 
receptors (Würtz, 2015). It further propagates the activation signal to adjacent platelets 
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contributing to additional platelet activation and TXA2 release, thereby initiating an 
amplification circle (Patrono, 2013; Würtz, 2015). TXA2 exerts its effect during primary 
haemostasis and large amounts are released during platelet aggregation. TXA2 (half-life 
= 30-40 seconds) is instantly hydrolysed non-enzymatically to its biologically inert 
metabolite TXB2 (half-life = 5-7 minutes), which is then rapidly metabolized to form 
urinary metabolites for renal clearance. Given the short-lived nature of TXA2, 
measurement of serum TXB2 or the urinary metabolites, 11-dehydro TXB2 and 2,3- dinor 
TXB2, reflects endogenous TXA2 synthesis with a greater degree of certainty than 
measurement of the parent compound (Patrono, 2013). 
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1.2 Antiplatelet Therapy 
1.2.1 Acetylsalicylic acid (Aspirin) and dual antiplatelet therapy (DAPT) 
Low Dose Aspirin (LDA) is the anchor of secondary prevention in CAD. Aspirin therapy 
is virtually taken for life in coronary artery disease patients (Levine et al., 2016). Aspirin 
is the backbone of dual antiplatelet therapy (DAPT); a term used precisely to refer to the 
concurrent use of aspirin and a P2Y12 receptor inhibitor (ticagrelor, prasugrel or 
clopidogrel) (Levine et al., 2016). It is the standard of care for prevention of cardiovascular 
outcomes in patients with CAD undergoing percutaneous coronary intervention (Lewis et 
al., 2013).  
The recommended dose of aspirin ranges from a once daily dose of 75 mg to 100 mg per 
orally in patients treated with DAPT (Levine et al., 2016). For non-DAPT, aspirin is 
usually taken at a dose of 75-325mg according to different guidelines but the optimal risk–
benefit ratio appears to be achieved with aspirin in a dose range of 75–150 mg/day 
(Montalescot et al., 2013). The latest version of “the Malaysian clinical practice guideline 
on management of Stable Coronary Artery Disease” (Ministry of Health, 2018) also 
adapts this dose. 
The two main goals of DAPT is prevention of stent thrombosis and reduction in systemic 
atherothrombotic events (Bittl, Baber, Bradley, & Wijeysundera, 2016). Generally, the 
length of DAPT after PCI with implantation of a newer-generation drug-eluting stents 
(DES) involves a simultaneous assessment between a decrease in stent thrombosis/MI and 
an increase in bleeding. Previously (Levine et al., 2011), a minimum duration of at least 
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12-month DAPT was endorsed irrespective of the clinical presentation. Recently (Bittl et 
al., 2016), with the advent of safer newer-generation DES, there has been a little paradigm 
shift, recommending a minimum of 3-6 month and a maximum of 12-month DAPT. 
Twelve months of DAPT was the most recommended duration based on trade-off between 
lower risk of complications related to bleeding and greater benefit of ischemic protection 
(Levine et al., 2016).  Prescription beyond 12 month requires a critical appraisal of the 
risk/benefit and may only be warranted in peculiar patient scenarios (Bittl et al., 2016; 
Levine et al., 2016).  
1.2.2 Pharmacology of aspirin 
Aspirin inhibits platelet reactivity by irreversibly inactivating the vital platelet protein, 
COX-1 which leads to persistent suppression of platelet TXA2 production and TXA2-
mediated platelet activation and aggregation (Patrono, 2015). This effect explains 
aspirin’s distinct (from other COX-1 inhibitors) efficacy in preventing atherothrombosis, 
as well as its common (with other antiplatelet agents) bleeding glitches (Patrono, 2015). 
Unlike with aspirin, COX-1 inhibition by other non-steroidal anti-inflammatory drugs 
(NSAIDs) is reversible. 
Aspirin attains a peak plasma level about 30 min after intake due to its prompt absorption 
in the stomach and upper small intestine. It has an oral bioavailability of 45 - 50%. COX-
1 enzyme is in control of the conversion of arachidonic acid to TXA2 (Eikelboom, Hirsh, 
Spencer, Baglin, & Weitz, 2012; Pettersen, Arnesen, & Seljeflot, 2015). Because aspirins’ 
inhibition of the COX-1 enzyme is irreversible, its antiplatelet effect lasts for the 7 to 10-
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day lifetime period of the platelets. The non-nucleated nature of platelets does not permit 
them to regenerate COX-1, making the platelet inhibitory effect to be renewed only 
through the generation of new platelets (Pettersen et al., 2015). This justifies the use of 
once daily dosing of aspirin despite its short half-life (15-20 mins).  
Aspirins’ mechanism of action is clearly depicted in Figure 1-1. A low-dose aspirin 
selectively inhibits COX-1, whereas a high-dose inhibits both COX-1 and COX-2. 
Prostaglandin H2 is converted to multiple prostanoids by tissue-specific isomerases. These 





Figure 1-1 Arachidonic Acid Metabolism and Mechanism of Action of Aspirin 
  
Adapted from (Eikelboom et al., 2012) COX=cyclooxygenase; DP=prostaglandin 
D2 receptor; EP=prostaglandin E2 receptor; FP=prostaglandinF2α receptor; 
HOX=hydroperoxidase; IP=prostacyclin receptor; TP=thromboxane receptor. 
Note: All Figures/ Tables reproduced in this thesis are with permission from the Publisher through 
Copyright Clearance Centre’s RightsLink® Digital Licensing and Rights Management service (Account 
Number 3001309278, Appendix VII) 
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1.2.3 Side effects of aspirin 
Despite the established efficacy, treatment with low-dose aspirin is accompanied by upper 
gastrointestinal (GI) side effects. These effects range from dyspepsia (point prevalence of 
31%), gastro-duodenal erosions (point prevalence of 60%), endoscopic peptic ulcer (3-
month incidence of 7%) to symptomatic or complicated ulcers (annual incidence of upper 
GI bleeding: 0.6%; relative risk of upper GI bleeding: 2.6) (Hsu & Tsai, 2015). The 
prevalence of upper GI ulcers is 10-40% amidst patients taking low-dose aspirin and 
aspirin heightens the risk of upper GI bleeding by up to 2-fold (Cryer & Mahaffey, 2014; 
Yamagata & Hiraishi, 2007). 
The adverse events related to LDA in the upper gastrointestinal tract are highly distinct 
and include esophagitis, petechiae, gastroduodenal ulcers and recurring peptic ulcers 
(Sostres & Lanas, 2011).  
1.2.4 Mechanism of gastrointestinal damage induced by aspirin 
Local Effects: Prostaglandin depletion through COX inhibition seems to be the main 
mechanism responsible for the development of aspirin-induced gastroduodenal ulcers, 
however its direct contact with the gastric and duodenal mucosa can also induce injury by 
influencing the gastric epithelial cell barrier (Sostres & Lanas, 2011). Enteric coated 
formulations were designed to decrease the incidence of gastroduodenal injury. 
Meanwhile, clinical experience and some meta-analysis show no pertinent distinction in 
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the incidence of mucosal damage between enteric coated and non-coated aspirin 
formulations (Derry & Loke, 2000; Sostres & Lanas, 2011). 
Systemic effects: The affinity of aspirin to COX-1 is more than 10-folds compared to 
COX-2 (Simmons, Botting, & Hla, 2004). COX-1 produces prostaglandins with 
cytoprotective effects while COX-2 produces PGs that mediate inflammation. Therefore, 
inhibition of COX-1 mediated PG synthesis is the primary mechanism through which 
aspirin results to injury to the upper GI mucosa (Lavie, Howden, Scheiman, & Tursi, 2017; 
Sostres & Lanas, 2011). 
1.2.5 Gastric toxicity as a reason for low dose aspirin therapy discontinuation 
Gastric toxicity is the major reason of non-adherence to aspirin therapy (Martín-Merino, 
Johansson, Bueno, & Rodríguez, 2012; Rodríguez, Cea-Soriano, Martín-Merino, & 
Johansson, 2011). Non-adherence on the other hand leads to treatment failure. A 
systematic review revealed a 10-50% poor compliance in patients taking low dose aspirin 
for prophylaxis against  CVD (Herlitz, Tóth, & Næsdal, 2010). A study that investigated 
the reasons for discontinuation of LDA in CVD prophylaxis reported “stomach problems” 
among the major causes for therapy disruption or termination (Lavie et al., 2017). 
1.2.6 Prevention and treatment of gastro-intestinal side effects of aspirin 
Current strategies to ameliorate the GI toxicity of LDA include prescription of alternative 
antiplatelet therapy, co-therapy with gastro-protective agents, eradication of H. pylori and 
endoscopic therapy (Cryer & Mahaffey, 2014; Sostres & Lanas, 2011). Limitations from 
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all these, ranges from increase in cost burden on the patient (associated with all the 
strategies) to invasiveness (in the case of endoscopy). Other strategies employed to 
specifically mitigate against LDA-induced GI toxicities include development of risk 
stratification tools to evaluate cardiovascular and GI risks to ease the clinical assessment 
(Abu-Assi et al., 2012; Lanas, Polo‐Tomás, & Casado‐Arroyo, 2013).  
It is important to point out once again that the assumption that enteric coated (EC) aspirin 
will give less gastric toxicity is unlikely as confirmed by previously large observational 
studies (de Abajo & García Rodríguez, 2001; Patrono & Rocca, 2017) and meta-analysis 
(Sostres & Gargallo, 2012), therefore EC aspirin is not superior to conventional 
formulation. 
The best available strategy for the prevention of LDA-induced GIT toxicity is the 
concomitant use of aspirin with medications that reduce gastric acid secretion. Proton 
pump inhibitors (PPIs) are preferred options than H2-receptor antagonists in this regard 
(Lavie et al., 2017). This may be explained by the PPIs, being acid-activated prodrugs, 
which bind covalently to cysteine residues on the luminal surface of the gastric H+/K+-
ATPase, thereby inhibiting acid secretion (Lavie et al., 2017). Also, a meta-analysis of 
randomized controlled trials that compared the preventive abilities of PPIs to H2-receptor 
antagonists in terms of LDA-induced GIT toxicities showed that the PPIs were superior to 
H2-receptor antagonists in this regard (Lavie et al., 2017). 
However, the option of concurrent usage with PPIs is also faced with some major 
challenges viz; LDA is taken for lifetime and therefore the economic burden on the patient 
is usually high and must be considered. Though researches on the pharmacodynamic drug-
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drug interaction of PPI and clopidogrel (used as DAPT with aspirin) showed mixed 
results, it is still worthy of consideration (Agewall et al., 2013; Scott, Owusu, & Hulot, 
2014; Sherwood et al., 2015). Moreover, the evidence that patient compliance to 
medication decreases with increase in the pill burden cannot be overemphasised (Farrell, 
French Merkley, & Ingar, 2013), coupled with the fact that most CAD patients have other 
co-morbidities requiring other medications. 
1.2.7 Aspirin resistance or high on-aspirin residual platelet reactivity (HRPR) 
The wide inter-individual variation witnessed in aspirin response despite an adequate 
decrease in thromboxane A2 indicates the possible existence of unknown alternative, 
biochemical and metabolic pathways that augments aspirin’s mechanism of action (Du, 
Lin, & Wang, 2016). Persistent platelet reactivity identified through a platelet function 
test is termed laboratory aspirin resistance (Hovens et al., 2007) whereas the occurrence 
of atherothrombotic events while still on aspirin therapy is termed clinical aspirin 
resistance (Hankey & Eikelboom, 2006). However, some researchers argue that, it is more 
appropriate to refer to the latter as “aspirin treatment failure” (Hankey & Eikelboom, 
2006) or “high on-aspirin residual platelet reactivity” (Pettersen et al., 2015). The term 
aspirin resistance will be used in this research and it refers to persistence of platelet 
reactivity identified through a laboratory test. 
1.2.8 Mechanism of aspirin resistance 
Many factors have been implicated in the phenomenon known as aspirin resistance. Many 
studies have found patient non-adherence to therapy as one of the reasons for the presumed 
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aspirin resistance after a witnessed aspirin consumption (Homoródi et al., 2016; Schwartz, 
Schwartz, Barber, Reeves, & De Franco, 2008). Other causes of presumed resistance 
include drug-drug interactions (e.g. with NSAIDs or PPIs) and the use of enteric coated 
aspirin (due to decreased absorption). Potential causes of true aspirin resistance include 
heightened platelet turnover such as that seen in diabetes and essential thrombocythemia 
(Grove, Hvas, Mortensen, Larsen, & Kristensen, 2011; Pascale et al., 2012; Rocca et al., 
2012), single nucleotide polymorphisms, inflammation, metabolic syndrome and miRNAs 
(Du et al., 2016; Floyd & Ferro, 2014). These have been summarized in Figure 1-2 below. 
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Figure 1-2  Mechanism of Aspirin Resistance 
 
Adapted from (Floyd & Ferro, 2014). The boxes labelled ‘aspirin resistance’ and 
‘aspirin treatment failure’ highlight the methodology to define the terms. [PPIs = proton 
pump inhibitors; NSAIDs = non-steroidal anti-inflammatory drugs; COX-1 = 
cyclooxygenase-1; TXA2 = thromboxane A2] (Floyd & Ferro, 2014) 
 
17 
1.2.9 Detection of aspirin resistance through platelet function tests  
The effects of aspirin on platelets have been monitored through several laboratory tests. 
The light transmittance aggregometry (LTA) was regarded as the gold standard (Pettersen 
et al., 2015). This is an ex vivo platelet aggregation test done with platelet rich plasma 
(PRP). This involves addition of one of the different agonists of platelet (arachidonic acid, 
collagen, serotonin, ristocetin or adenosine-diphosphate, depending on the study 
rationale) and measuring the increase in light transmittance through the optically dense 
sample. The PRP should ideally become clearer after the addition of an agonist due to 
precipitation of platelet aggregates. A photometer then measures the change in light 
transmittance as a percentage from 0-100%. Zero percent implies no aggregation at all 
while 100% indicates total aggregation of platelets. The technique is however too 
laborious, time consuming and requires a highly skilled and experienced operator. Other 
non-point of care tests includes; lumiaggregometry and impedance aggregometry on 
whole blood. Point of care analysis frequently used include Multiple Electrode 
Aggregometry (MEA), Platelet Function Analyzer-100 (PFA-100; Dade Behring), 
Plateletworks (Helena Laboratories, Beaumont, Texas) and the VerifyNow aspirin assay 
(Accumetrics, San Diego, California). 
The PFA-100 computes the duration it takes platelets to block the orifice of its test 
cartridges when whole blood is passed through under shear stress. The time taken by 
platelets to halt the citrated whole blood flow due to blockage of the orifice is referred to 
as closure time (CT). The cartridges either contain collagen together with epinephrine 
(CEPI) or collagen together with ADP (CADP). The CEPI is primarily used to measure 
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platelet inhibition due to aspirin therapy while the CADP is used to identify other intrinsic 
platelet defects like Von Willebrand disease. The technique is very sensitive but its 
dependence on Von Willebrand factor (vWF) and platelet haematocrit, and its expensive 
price are its major limitations (Gaoyu et al., 2016).  
The VerifyNow aspirin Test uses arachidonic acid as agonist to trigger off platelets. It 
functions by quantifying platelet function based upon the capacity of activated platelets to 
bind fibrinogen. Fibrinogen-coated microparticles clump together in whole blood 
proportionate to the number of unblocked platelet GP IIb/IIIa receptors. Transmission of 
light increases as activated platelets bind and agglutinate fibrinogen-coated beads.  This 
device computes the change in optical signal caused by clumping together of platelets and 
records the result as aspirin reaction units (ARU). A value < 550 ARU is consistent with 
aspirin-induced platelet inhibition while a value ≥550 ARU implies non-aspirin induced 
platelet dysfunction. The reference range value for pre-aspirin samples is 620-672 ARU 
(Accumetrics Inc., 2006).  
1.2.10 Detection of aspirin resistance through thromboxane metabolites 
Thromboxane metabolites are also used to assess the effect of aspirin on platelets. They 
have the advantage of directly measuring the effect of aspirin on COX-1. Thromboxane 
A2 is the major product of the platelet arachidonic Acid metabolism. However, its transient 
nature (t1/2=30-40s) due to rapid hydrolysis into TXB2 makes its measurement non-
practical. TXB2 is biologically inactive but a stable product. It’s metabolised and excreted 
into urine as 2,3-dinor-TXB2 and in 11-dehydro-TXB2. The latter is abundantly more than 
the former in urine. This makes it a target for the measurement of aspirin’s effect on 
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platelet COX-1. In inflammatory diseases and other pathologic conditions, up to 30% of 
urinary metabolites may be derived from non-platelet sources. This makes the 
measurement of urinary thromboxanes to be non-specific for monitoring the effects of 
aspirin. Due to the ease and non-invasiveness of obtaining urine samples, urinary 11-
dehydro-TXB2 is still determined with the aid of the FDA approved AspirinWorks® test 
(Corgenix, Broomfield, Colorado) or other available kits, but it is usually normalised to 
creatinine to increase its predictive value.  
On the contrary, serum thromboxane B2 (STxB2), exhibits the overall ability of platelet to 
synthesize TXA2. This renders the contribution of other haematocytes in its synthesis to 
be negligible and hence making STxB2 the most precise method to test the pharmacologic 
effect of aspirin on platelet (Cattaneo, 2013; Frelinger et al., 2008; Grove et al., 2010; 
Halvorsen et al., 2014; Rozalski, Watala, & Golanski, 2014). These reasons guided in the 
choice of STxB2 enzyme linked immunosorbent assay (ELISA) to measure aspirin 
response in this research. 
Serum thromboxane B2 has been used in so many researches to measure the effect of 
aspirin on platelets. However, the major limitation of its use is the absence of a universally 
accepted cut-off value to define aspirin non-responsiveness (Fontana et al., 2010; 
Frelinger et al., 2009; Reny et al., 2012). The values are highly kit specific. Previous 
studies have found the use of receiver operator characteristic analysis of serum TxB2 
levels in relation to major adverse cardiovascular (Fontana et al., 2010; Frelinger et al., 
2009; Reny et al., 2012) and the selection of at least 95% inhibition (Patrono & Rocca, 
2007) of STxB2 (compared to the pre-aspirin STxB2 value) to increase its predictive value. 
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1.3 Systems biology and the “omics” sciences 
“Systems biology is the study of the molecular, biochemical, and supramolecular 
networks, along with their connections as well as interactions with environmental factors 
in order to determine an intricate biological perturbation of the living organism”(Louridas, 
Kanonidis, & Lourida, 2010). This is an integrative approach that investigates biological 
“Omics” and the environmental factors that interfere with their systematic connections. 
“Omics” is a somewhat new terminology utilised in referring to the fields of genomics, 
epigenomics, transcriptomics, proteomics, metabolomics, microbiomics and a host of 
others. Unlike conventional biology, systems biology takes into account the connections 
and interactions between the biological processes in living system and their environment. 
Genomics centres on determining genetic variants associated with a disease, response to 
a treatment, or future patient prognosis (Hasin, Seldin, & Lusis, 2017). Genomics is the 
most prominent of all the omics fields. However, epigenomics deals with genome-wide 
characterization of reversible alterations of DNA or its associated proteins, like DNA 
methylation or histone acetylation (Romanoski, Glass, Stunnenberg, Wilson, & 
Almouzni, 2015). Whereas, transcriptomics investigate RNA levels genome-wide, both 
qualitatively (which transcripts are present, identification of novel splice sites, RNA 
editing sites) and quantitatively (how much of each transcript is expressed) (Lowe, 
Shirley, Bleackley, Dolan, & Shafee, 2017). Proteomics is used to measure peptide 
abundance, modification, and interaction. While, microbiomics is a fast-growing field in 
which all the microorganisms of a given community are studied together (Hasin et al., 
2017). When any of the omics is studied in relation to the effect of drugs, the prefix 
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“pharmaco” is attached, e.g. pharmaco-genomics. The relationship between the omics is 




Figure 1-3  Relationship Between the Omics Sciences 
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1.4 Metabonomics and metabolomics 
Metabonomics is defined as ‘‘The study of the metabolic response of organisms to disease, 
environmental change or genetic modification” (Lindon, Nicholson, Holmes, & Everett, 
2000). Metabolomics on the other hand is defined as “The holistic and quantitative 
measurement of all the metabolites in a biological system”(Fiehn, 2002).  The definition 
of metabolomics seems impractical, considering the complexity and unexhaustive number 
of metabolites in a biological system. Although the terms are sometimes used 
interchangeably in the literature, it is more prudent to stick to the term, metabonomics. 
1.5 Personalised medicine 
Personalised medicine is defined as “the use of the collective knowledge (genetic or 
otherwise) about an individual to predict disease susceptibility, disease prognosis, or 
treatment response and as such improve that individual’s health”(Redekop & Mladsi, 
2013). Personalised medicine is also referred to as precision medicine or stratified 
medicine (Pokorska-Bocci et al., 2014). The present-day idea of personalised medicine is 
built upon pharmacogenomics to predict the effect of patient gene mutations on treatment 
outcomes. However, the fact that the effects of drugs on humans and vice versa is 
influenced by other environmental factors like the microbiome of the patient, asides their 
genetic profiles has constrained this concept (Everett, 2017). This made the clinical utility 
of pharmacogenomics less than earlier envisaged.  
Pharmacometabonomics, however, can account for both genetic and environmental 
factors that affects the efficacy, safety, metabolism, transport, and pharmacokinetics of 
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drugs. Combination of both omics is therefore hoped to be able to provide more sensitive 
and specific predictions of drug safety and efficacy (Everett, 2017).  
1.6 Pharmacometabonomics  
In the year 2000, a new methodology that is interested in the prediction of drug effects 
using pre-dose metabolic profiles of biofluids was found and the outcomes published in 
2006 (Everett, 2015). This was termed Pharmacometabonomics. It is defined as “the 
prediction of the outcome (e.g., toxicity or efficacy) of a drug or xenobiotic in an 
individual based on a mathematical model of pre-intervention metabolite signatures” 
(Clayton et al., 2006).  
It is pertinent to highlight that Pharmacometabonomics is precisely an example of a 
broader group of experiments labelled as predictive metabonomics, where pre-event 
metabolite profiles may be utilised to predict post event outcomes; in this case, the event 
is drug dosing. The advantage of this approach is it that, it does not only reveal the 
variation in the genetic and metabolic profiles, it also expresses the environmental 
interaction with them (Guţiu et al., 2010).  Several studies have shown the success of this 
approach in predicting efficacy and toxicity of drugs in animals and humans (Clayton, 
Baker, Lindon, Everett, & Nicholson, 2009; Everett, 2015; Everett, Loo, & Pullen, 2013; 
Park et al., 2013; Zhu et al., 2013). Few of these studies were related to response 
variability/resistance to aspirin (Ellero-Simatos et al., 2014; Ellero‐Simatos et al., 2015; 
Lewis et al., 2013), but none was related to the gastric toxicity of aspirin. This can be a 
comprehensive, fast, economical, and less invasive approach to predict the gastric toxicity 
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of aspirin and thus help in the personalization of its therapy.  The findings of some 
pharmacometabonomic studies are summarised in Table 1-1 below.
